Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash from Financing Activities (2020 - 2026)

Cytek Biosciences filings provide 6 years of Cash from Financing Activities readings, the most recent being -$1.2 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 66.32% to -$1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.4 million, a 15.11% increase, with the full-year FY2025 number at -$13.4 million, up 15.11% from a year prior.
  • Cash from Financing Activities hit -$1.2 million in Q4 2025 for Cytek Biosciences, down from $1.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $217.1 million in Q3 2021 to a low of -$33.8 million in Q4 2023.
  • Median Cash from Financing Activities over the past 5 years was $17000.0 (2021), compared with a mean of $7.8 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 22547.06% in 2022 and later plummeted 5438.06% in 2023.
  • Cytek Biosciences' Cash from Financing Activities stood at $17000.0 in 2021, then skyrocketed by 22547.06% to $3.8 million in 2022, then plummeted by 976.73% to -$33.8 million in 2023, then soared by 89.22% to -$3.6 million in 2024, then soared by 66.32% to -$1.2 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$1.2 million (Q4 2025), $1.9 million (Q3 2025), and -$2.6 million (Q2 2025) per Business Quant data.